Serum Institute of India Pvt Ltd
About
The Serum Institute of India was established in 1966 by Dr. Cyrus Poonawalla with the goal of producing essential immuno-biological products. The company manufactures vaccines for diseases such as polio, diphtheria, tetanus, measles, and COVID-19. The institute provides vaccines to more than 170 countries, placing a substantial emphasis on low- and middle-income countries. The COVID-19 vaccine, Covishield, developed in collaboration with AstraZeneca and Oxford University, has been widely distributed globally. Serum Institute operates state-of-the-art manufacturing facilities in Pune, Maharashtra, with a combined capacity of over 4 billion doses per year. The company operates as a subsidiary of the Cyrus Poonawalla Group. The Serum Institute of India holds the top position among biotechnology companies in India.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 11421 4.3% | 10953 -59.1% | 26802 202.8% | 8851 48.2% | 5972 1.2% | 5903 18.4% | 4984 8.1% | 4611 -1.9% | 4701 16.1% | 4050 9.8% | 3689 36.7% | 2698 48.9% | 1813 64.2% | 1104 28.6% | 858 - |
| Net Operating Income (INR Cr) | 9549 -6.29% | 10190 -60.27% | 25645 256.13% | 7201 32.23% | 5446 3.97% | 5238 21.28% | 4319 5.52% | 4093 -6.55% | 4380 17.20% | 3737 5.46% | 3544 40.39% | 2524 47.19% | 1715 89.39% | 905 28.28% | 706 0.00% |
| Profit (INR Cr) | 4278 2.2% | 4187 -62.3% | 11116 185.7% | 3891 72.9% | 2251 0.0% | 2252 17.8% | 1912 -7.1% | 2057 -5.6% | 2179 11.0% | 1964 12.8% | 1741 34.4% | 1295 56.4% | 828 90.9% | 434 51.1% | 287 - |
| Assets (INR Cr) | 42099 12.1% | 37541 11.5% | 33659 49.7% | 22491 24.2% | 18110 13.2% | 15998 17.0% | 13677 15.1% | 11886 19.9% | 9911 24.9% | 7938 20.5% | 6589 35.2% | 4875 39.4% | 3498 38.4% | 2527 24.7% | 2027 - |
| Net Worth (INR Cr) | 41187 11.6% | 36902 12.1% | 32933 50.8% | 21839 21.8% | 17929 13.7% | 15767 16.1% | 13581 15.0% | 11815 21.1% | 9759 25.4% | 7781 31.3% | 5926 42.0% | 4175 51.4% | 2758 34.1% | 2056 26.4% | 1627 0.0% |
| Employee Cost (INR Cr) | 1458 6.6% | 1368 -28.6% | 1917 42.0% | 1350 58.3% | 853 -9.5% | 942 19.7% | 787 8.6% | 725 13.3% | 640 35.1% | 474 4.2% | 455 39.7% | 325 24.1% | 262 50.0% | 175 53.0% | 114 - |
| Interest Cost (INR Cr) | 65 | 64 | 70 | 43 | 26 | 27 | 10 | 14 | 9 | 15 | 25 | 33 | 24 | 10 | 20 |
| Cash & Bank Balance (INR Cr) | 1072 | 733 | 953 | 1697 | 321 | 369 | 211 | 146 | 408 | 73 | 259 | 57 | 48 | 51 | 121 |
| Total Debt (INR Cr) | 302 | 57 | 191 | 196 | 49 | 140 | 5 | 13 | 99 | 110 | 618 | 655 | 692 | 471 | 400 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 37.5% | 38.2% | 41.5% | 44.0% | 37.7% | 38.2% | 38.4% | 44.6% | 46.4% | 48.5% | 47.2% | 48.0% | 45.7% | 39.3% | 33.5% |
| Profit As % Of Assets | 10.2% | 11.2% | 33.0% | 17.3% | 12.4% | 14.1% | 14.0% | 17.3% | 22.0% | 24.7% | 26.4% | 26.6% | 23.7% | 17.2% | 14.2% |
| Profit As % Of Networth | 10.4% | 11.4% | 33.8% | 17.8% | 12.6% | 14.3% | 14.1% | 17.4% | 22.3% | 25.2% | 29.4% | 31.0% | 30.0% | 21.1% | 17.7% |
| Interest Cost to EBITDA % | 1.4% | 1.1% | 0.4% | 1.0% | 0.9% | 1.0% | 0.5% | 0.6% | 0.4% | 0.7% | 1.2% | 2.2% | 2.4% | 2.7% | 7.8% |
| Debt to Equity Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.10 | 0.16 | 0.25 | 0.23 | 0.25 |
| RONW | 9.1% | 12.0% | 40.6% | 16.2% | 13.4% | 15.4% | 15.1% | 19.1% | 24.9% | 28.7% | 34.5% | 37.4% | 34.4% | 20.6% | 15.9% |
| ROCE | 11.5% | 15.2% | 60.6% | 20.3% | 17.4% | 20.6% | 18.9% | 22.9% | 29.5% | 30.1% | 34.6% | 34.4% | 31.4% | 17.3% | 14.5% |